Involvement of Eotaxins (CCL11, CCL24, CCL26) in Pathogenesis of Osteopenia and Osteoporosis
-
Hadis AHMADI
,
Hossein KHORRAMDELAZAD
,
Gholamhossein HASSANSHAHI
,
Mitra ABBASI FARD
,
Zahra AHMADI
,
Mojgan NOROOZI KARIMABAD
,
Majid MOLLAHOSSEINI
Abstract
Background: The purpose of this study was to investigate the role of eotaxin family members including C-C motif chemokine 11 (CCL11), C-C motif chemokine 24 (CCL24), and C-C motif chemokine 26 (CCL26) as the subgroups of CC-chemokine in patients affected with osteoporosis and osteopenia.
Methods: Overall, 19 osteoporotic patients, 18 osteopenic individuals, and 20 healthy subjects were recruited in this study. The bone mineral density (BMD) was then measured at the lumbar spine (L1-L4) and the hip (femoral neck and total hip) using dual-energy X-ray absorptiometry for diagnosis of bone density and related disorders. Additionally, enzyme-linked immunosorbent assay (ELISA) technique was employed to measure the serum levels of CCL11, CCL24, and CCL26.
Results: The circulating levels of CCL11, CCL24, and CCL26 had been increased in both groups of patients with osteopenia and osteoporosis compared to those in healthy subjects (P<0.05); while no significant difference was observed between serum levels of these chemokines in such patients.
Conclusion: Eotaxins can play a role in the pathogenesis of osteoporosis and osteopenia; however, further studies are needed to clarify various roles of eotaxins in the pathophysiology of osteoporosis and osteopenia.
1. Siris E, Adler R, Bilezikian J, et al (2014). The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int, 25:1439-1443.
2. Hodsman AB, Leslie WD, Tsang JF,et al (2008). 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med, 168:2261-2267.
3. Sims NA, Gooi JH (2008). Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol, 19(5):444-51.
4. Boyce B, Yao Z, Xing L (2009). Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr, 19(3):171-80.
5. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, et al (2010). RANK/RANKL/OPG role in distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 109:679-686.
6. Guihard P, Danger Y, Brounais B, et al (2012). Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells, 30:762-772.
7. Farangis F, Majid M, Gholamhossein H, et al (2017). CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients. J Biomed Res, 31(5): 468–470.
8. Harvey B, Kaymakcalan Z (2016). AB0064 Adalimumab Is More Effective than Etanercept in Reducing Chemotaxis of Human Monocytes in Response To TNF-Induced Chemokine Secretion from Human Osteoclast Precursors. Ann Rheum Dis, 75(Suppl 2):918.3-919
9. Bagheri V, Khorramdelazad H, Hassanshahi G, et al (2018). CXCL12 and CXCR4 in the Peripheral Blood of Patients with Parkinson’s Disease. Neuroimmunomodulation, 25(4):1-5.
10. Selvaraj P, Harishankar M, Singh B, et al (2012). Effect of vitamin D 3 on chemokine expression in pulmonary tuberculosis. Cytokine, 60:212-219.
11. Moogooei M, Shamaei M, Khorramdelazad H, et al (2015). The intricate expression of CC chemokines in glial tumors: evidence for involvement of CCL2 and CCL5 but not CCL11. Acta Med Iran, 53(12):770-777.
12. Bao L, Shi VY, Chan LS (2012). IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis. Mol Immunol, 50:91-97.
13. Grozdanovic MM, Rousslang LK, Abdelkarim H, et al (2017). A novel biased antagonist of the eotaxin-CCR3 pathway in eosinophils. J Allergy Clin Immunol, 139(2):AB163.
14. Kominsky SL, Abdelmagid SM, Doucet M, et al (2008). Macrophage Inflammatory Protein–1δ: A Novel Osteoclast Stimulating Factor Secreted by Renal Cell Carcinoma Bone Metastasis. Cancer Res, 68:1261-1266.
15. Kindstedt E (2017). Novel Insights into Inflammatory Disturbed Bone Remodelling. Umeå universitet. https://www.diva-portal.org/smash/get/diva2:1142987/FULLTEXT01.pdf
16. Camacho PM, Petak SM, Binkley N, et al (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016. Endocr Pract, 22(Suppl 4):1-42.
17. Keramat A, Patwardhan B, Larijani B, et al (2008). The assessment of osteoporosis risk factors in Iranian women compared with Indian women. BMC Musculoskelet Disord, 9:28.
18. Ishii T, Kikuta J, Kubo A, Ishii MJIB (2010). Control of osteoclast precursor migration: a novel point of control for osteoclastogenesis and bone homeostasis. IBMS BoneKEy, 7:279-286.
19. Xuan W, Feng X, Qian C, et al (2017). Osteoclast differentiation gene expression profiling reveals chemokine CCL4 mediates RANKL‐induced osteoclast migration and invasion via PI3K pathway. Cell Biochem Funct, 35:171-177.
20. Provost V, Larose MC, Langlois A, et al (2013). CCL26/eotaxin‐3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin‐1 and CCL24/eotaxin‐2. J Leukoc Biol, 94:213-222.
21. Kindstedt E, Holm CK, Sulniute R, et al (2017). CCL11, a novel mediator of inflammatory bone resorption. Sci Rep, 7:5334.
22. Khan UA, Hashimi SM, Khan S, et al (2014). Differential expression of chemokines, chemokine receptors and proteinases by foreign body giant cells (FBGCs) and osteoclasts. J Cell Biochem, 115:1290-1298.
23. Lean JM, Murphy C, Fuller K, Chambers TJ (2002). CCL9/MIP‐1γ and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem, 87:386-393.
24. Georgess D, Machuca-Gayet I, Blangy A, Jurdic P (2014). Podosome organization drives osteoclast-mediated bone resorption. Cell Adh Migr, 8:192-204.
25. Grassi F, Manferdini C, Cattini L, et al (2011). T cell suppression by osteoclasts in vitro. J Cell Physiol, 226:982-990.
26. Alblowi J, Tian C, Siqueira MF, et al (2013). Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone, 53:294-300.
27. Hoshino A, Iimura T, Ueha S, et al (2010). Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts. J Biol Chem, 285(37):28826-37.
2. Hodsman AB, Leslie WD, Tsang JF,et al (2008). 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med, 168:2261-2267.
3. Sims NA, Gooi JH (2008). Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol, 19(5):444-51.
4. Boyce B, Yao Z, Xing L (2009). Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr, 19(3):171-80.
5. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, et al (2010). RANK/RANKL/OPG role in distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 109:679-686.
6. Guihard P, Danger Y, Brounais B, et al (2012). Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells, 30:762-772.
7. Farangis F, Majid M, Gholamhossein H, et al (2017). CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients. J Biomed Res, 31(5): 468–470.
8. Harvey B, Kaymakcalan Z (2016). AB0064 Adalimumab Is More Effective than Etanercept in Reducing Chemotaxis of Human Monocytes in Response To TNF-Induced Chemokine Secretion from Human Osteoclast Precursors. Ann Rheum Dis, 75(Suppl 2):918.3-919
9. Bagheri V, Khorramdelazad H, Hassanshahi G, et al (2018). CXCL12 and CXCR4 in the Peripheral Blood of Patients with Parkinson’s Disease. Neuroimmunomodulation, 25(4):1-5.
10. Selvaraj P, Harishankar M, Singh B, et al (2012). Effect of vitamin D 3 on chemokine expression in pulmonary tuberculosis. Cytokine, 60:212-219.
11. Moogooei M, Shamaei M, Khorramdelazad H, et al (2015). The intricate expression of CC chemokines in glial tumors: evidence for involvement of CCL2 and CCL5 but not CCL11. Acta Med Iran, 53(12):770-777.
12. Bao L, Shi VY, Chan LS (2012). IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis. Mol Immunol, 50:91-97.
13. Grozdanovic MM, Rousslang LK, Abdelkarim H, et al (2017). A novel biased antagonist of the eotaxin-CCR3 pathway in eosinophils. J Allergy Clin Immunol, 139(2):AB163.
14. Kominsky SL, Abdelmagid SM, Doucet M, et al (2008). Macrophage Inflammatory Protein–1δ: A Novel Osteoclast Stimulating Factor Secreted by Renal Cell Carcinoma Bone Metastasis. Cancer Res, 68:1261-1266.
15. Kindstedt E (2017). Novel Insights into Inflammatory Disturbed Bone Remodelling. Umeå universitet. https://www.diva-portal.org/smash/get/diva2:1142987/FULLTEXT01.pdf
16. Camacho PM, Petak SM, Binkley N, et al (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016. Endocr Pract, 22(Suppl 4):1-42.
17. Keramat A, Patwardhan B, Larijani B, et al (2008). The assessment of osteoporosis risk factors in Iranian women compared with Indian women. BMC Musculoskelet Disord, 9:28.
18. Ishii T, Kikuta J, Kubo A, Ishii MJIB (2010). Control of osteoclast precursor migration: a novel point of control for osteoclastogenesis and bone homeostasis. IBMS BoneKEy, 7:279-286.
19. Xuan W, Feng X, Qian C, et al (2017). Osteoclast differentiation gene expression profiling reveals chemokine CCL4 mediates RANKL‐induced osteoclast migration and invasion via PI3K pathway. Cell Biochem Funct, 35:171-177.
20. Provost V, Larose MC, Langlois A, et al (2013). CCL26/eotaxin‐3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin‐1 and CCL24/eotaxin‐2. J Leukoc Biol, 94:213-222.
21. Kindstedt E, Holm CK, Sulniute R, et al (2017). CCL11, a novel mediator of inflammatory bone resorption. Sci Rep, 7:5334.
22. Khan UA, Hashimi SM, Khan S, et al (2014). Differential expression of chemokines, chemokine receptors and proteinases by foreign body giant cells (FBGCs) and osteoclasts. J Cell Biochem, 115:1290-1298.
23. Lean JM, Murphy C, Fuller K, Chambers TJ (2002). CCL9/MIP‐1γ and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem, 87:386-393.
24. Georgess D, Machuca-Gayet I, Blangy A, Jurdic P (2014). Podosome organization drives osteoclast-mediated bone resorption. Cell Adh Migr, 8:192-204.
25. Grassi F, Manferdini C, Cattini L, et al (2011). T cell suppression by osteoclasts in vitro. J Cell Physiol, 226:982-990.
26. Alblowi J, Tian C, Siqueira MF, et al (2013). Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone, 53:294-300.
27. Hoshino A, Iimura T, Ueha S, et al (2010). Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts. J Biol Chem, 285(37):28826-37.
| Files | ||
| Issue | Vol 49 No 9 (2020) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v49i9.4098 | |
| PMCID | PMC7898105 | |
| PMID | 33643953 | |
| Keywords | ||
| Eotaxins Protein Human Osteopenia Osteoporosis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
AHMADI H, KHORRAMDELAZAD H, HASSANSHAHI G, ABBASI FARD M, AHMADI Z, NOROOZI KARIMABAD M, MOLLAHOSSEINI M. Involvement of Eotaxins (CCL11, CCL24, CCL26) in Pathogenesis of Osteopenia and Osteoporosis. Iran J Public Health. 2020;49(9):1769-1775.
